Although CIC::NUTM1 has the lowest metastatic rate amongst the CIC-rearranged sarcomas, eight of the fourteen patients featured in the case reports died of their disease despite only two experiencing metastatic progression and amidst the use of surgical resection, chemotherapy, and radiotherapy in most of these patients (Le Loarer et al., 2019; Yang et al., 2022). Here, NUTM1 is linked to sarcoma.